EcoDrugPlus

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSCSAG00000006705
Gene Symbol: HTR7
3 Cross references
220 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Acidic Ribosomal Protein P1-Like

Ensembl ID : ENSCSAG00000013638
Gene Symbol: LOC103223570
3 Cross references
176 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L13-Like

Ensembl ID : ENSCSAG00000000476
Gene Symbol: LOC103218934
3 Cross references
247 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L22

Ensembl ID : ENSCSAG00000019575
Gene Symbol: LOC103229403
3 Cross references
230 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L24-Like

Ensembl ID : ENSCSAG00000000058
Gene Symbol: LOC103232334
3 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L27a-Like

Ensembl ID : ENSCSAG00000019253
Gene Symbol: LOC103238280
3 Cross references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L39

Ensembl ID : ENSCSAG00000019753
Gene Symbol: LOC103239219
3 Cross references
409 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L6

Ensembl ID : ENSCSAG00000013863
Gene Symbol: LOC103246174
3 Cross references
306 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L6-Like

Ensembl ID : ENSCSAG00000019405
Gene Symbol: LOC103228929
3 Cross references
306 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L6-Like

Ensembl ID : ENSCSAG00000018727
Gene Symbol: LOC103235696
3 Cross references
306 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L7-Like

Ensembl ID : ENSCSAG00000019542
Gene Symbol: LOC103231744
3 Cross references
252 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L7a-Like

Ensembl ID : ENSCSAG00000013484
Gene Symbol: LOC103244003
3 Cross references
177 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).